ArticleCaspian journal of internal medicine2025
Effectiveness of sumac seed
Article in Caspian journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes or non-insulin-dependent diabetes is one of the most common types of diabetes. The existing treatments for type 2 diabetes have not been able to completely cure this disease in affected cases. Sumac showed antioxidants, reducing blood sugar and serum cholesterol levels. In this study, according to the positive effects of sumac in diabetic diseases, it was tried that sumac capsules were prepared from the aqueous extract of this plant, and its effect on the factors of diabetes in patients was evaluated. Methods: This double-blind randomized controlled clinical trial was conducted on sixty type 2diabetic volunteers. The volunteers were divided into two groups, control, and sumac supplement groups. Baseline venous blood samples were collected after overnight fasting before intervention and a second sampling was done in the 12th week. Hb1AC, FBS, TG, TC, LDL-C, and HDL-C were measured via commercial kits. Results: FBS, HDL-C, and HbA1C measured in the sumac supplement group were significantly different (p<0.01) compared to the control group and baseline of the study. Moreover, there is no significant difference in levels of the sumac supplement group (CHOL, LDL-C, and TG) compared to the control group and baseline of the study (p>0.05). Conclusion: Our data confirmed the anti-diabetic effect of sumac in patients. Because of sumac safety, it seems that sumac capsules can be used for the treatment of diabetic patients along with routine chemical drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.